Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Nov;60(5):469-76.
doi: 10.1111/j.1365-2125.2005.02476.x.

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

Gregory Holmes  1 , Lawrence Galitz, Peter Hu, William Lyness
Affiliations
Clinical Trial

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

Gregory Holmes et al. Br J Clin Pharmacol. 2005 Nov.

Abstract

Aims: To assess the effects of body mass index, renal impairment (creatinine clearance), and hepatic impairment (Child-Pugh Score) on the pharmacokinetics of insulin aspart.

Methods: Pharmacokinetics of insulin aspart (injected subcutaneously in the abdomen immediately before a Boost standardized meal) were characterized in: (1) diabetic subjects with four ranges of BMI values (n = 23); (2) diabetic subjects with varying degrees of renal impairment (normal, n = 6 vs. two ranges of impairment, n = 12); and (3) nondiabetic patients with varying degrees of hepatic impairment (normal, n = 6 vs. three ranges of impairment, n = 18).

Results: There was no correlation between any pharmacokinetic variable and the degree of renal or hepatic impairment. Increasing obesity was associated with a decreased apparent clearance per kg body weight (beta = -0.0005, SE = 0.0001; P = 0.002), an increased t((1/2)) (beta = 3.513, SE = 1.636; P = 0.044), and an increased ln(AUC(0-360)) and ln(AUC(0-1440)) (beta = 0.030, SE = 0.013; P = 0.032 and beta = 0.039, SE = 0.0132; P = 0.006, respectively). However, obesity-related changes were smaller than individual variations in parameters.

Conclusions: Renal impairment, hepatic impairment, or BMI do not affect the pharmacokinetics of insulin aspart in a clinically significant manner.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean plasma concentration-vs.-time profiles for insulin aspart following subcutaneous injection; Panel A: profiles by BMI category. Range I (•), Rangel II (○), Rangel III (▪), Rangel IV (□). Panel B: profiles for degree of renal impairment. Normal (•), mild (○), moderate (▪), severe (□); Panel C: profiles for degree of hepatic impairment. Normal (•), mild (○), moderate (▪), severe (□)
Figure 2
Figure 2
Effects of obesity on the pharmacokinetics of insulin aspart; Panel A: CL/F vs. BMI value; Panel B: ln(Cmax) vs. BMI value; Panel C: ln(AUC0–1440) vs. BMI value
Figure 3
Figure 3
Effects of renal impairment on the pharmacokinetics of insulin aspart; Panel A: CL/F vs. creatinine clearance; Panel B: ln(Cmax) vs. creatinine clearance; Panel C: ln(AUC0–1440) vs. creatinine clearance
Figure 4
Figure 4
Effects of hepatic impairment on the pharmacokinetics of insulin aspart; Panel A: CL/F vs. Child-Pugh Score; Panel B: ln(Cmax) vs. Child-Pugh Score; Panel C: ln(AUC0–1440) vs. Child-Pugh Score
See this image and copyright information in PMC

References

    1. Setter SM, Corbett CF, Campbell RK, White JR. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother. 2000;34(12):1423–31. - PubMed
    1. Clauson PG, Linde B. Absorption of rapid acting insulin in obese and non-obese NIDDM subjects. Diabetes Care. 1995;18:986–91. - PubMed
    1. DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia: Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest. 1978;62:425–35. - PMC - PubMed
    1. Foss MC, Gouveia LMFB, Moyses Neto M, Paccola GM, Piccinato CE. Effect of hemodialysis on peripheral glucose metabolism of patients with chronic renal failure. Nephron. 1996;73:48–53. - PubMed
    1. Fliser D, Pacini G, Engerleither R, Kautzky-Willer A, Prager R, Franek E, Ritz E. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Intl. 1998;53:343–1347. - PubMed

Publication types